ConforMIS Inc (NASDAQ:CFMS) has been assigned a consensus recommendation of “Hold” from the nine ratings firms that are presently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and four have given a buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $4.90.
Several brokerages have issued reports on CFMS. BTIG Research reaffirmed a “buy” rating and set a $4.00 target price on shares of ConforMIS in a research note on Wednesday, January 10th. JPMorgan Chase & Co. cut shares of ConforMIS from a “neutral” rating to an “underweight” rating in a research report on Tuesday, January 2nd. Zacks Investment Research cut shares of ConforMIS from a “hold” rating to a “sell” rating in a research report on Wednesday, January 24th. Canaccord Genuity reissued a “hold” rating on shares of ConforMIS in a research report on Monday. Finally, Cowen began coverage on shares of ConforMIS in a research report on Wednesday, February 21st. They set an “outperform” rating and a $4.00 price target on the stock.
Shares of ConforMIS (CFMS) traded down $0.03 on Friday, reaching $1.42. 82,288 shares of the company’s stock traded hands, compared to its average volume of 704,184. ConforMIS has a 52 week low of $1.15 and a 52 week high of $5.98. The company has a debt-to-equity ratio of 0.52, a quick ratio of 5.38 and a current ratio of 6.19. The firm has a market cap of $87.64, a PE ratio of -1.17 and a beta of 1.22.
In other news, CEO Mark A. Augusti sold 16,548 shares of the business’s stock in a transaction dated Tuesday, December 19th. The shares were sold at an average price of $2.27, for a total transaction of $37,563.96. Following the transaction, the chief executive officer now owns 285,007 shares of the company’s stock, valued at approximately $646,965.89. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In the last three months, insiders have sold 39,502 shares of company stock worth $79,928. Corporate insiders own 9.55% of the company’s stock.
Hedge funds have recently made changes to their positions in the company. Citadel Advisors LLC boosted its position in shares of ConforMIS by 331.2% during the 3rd quarter. Citadel Advisors LLC now owns 113,972 shares of the medical instruments supplier’s stock valued at $401,000 after acquiring an additional 87,540 shares during the last quarter. Ark Investment Management LLC raised its holdings in ConforMIS by 208.5% in the 2nd quarter. Ark Investment Management LLC now owns 192,378 shares of the medical instruments supplier’s stock valued at $825,000 after buying an additional 130,009 shares during the period. Prosight Management LP purchased a new stake in ConforMIS in the 4th quarter valued at about $952,000. Northern Trust Corp raised its holdings in ConforMIS by 15.2% in the 2nd quarter. Northern Trust Corp now owns 454,468 shares of the medical instruments supplier’s stock valued at $1,950,000 after buying an additional 60,034 shares during the period. Finally, Granite Investment Partners LLC purchased a new stake in ConforMIS in the 3rd quarter valued at about $859,000. 24.21% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This report was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://stocknewstimes.com/2018/03/13/conformis-inc-cfms-receives-4-75-average-price-target-from-analysts.html.
ConforMIS Company Profile
ConforMIS, Inc is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints.
Receive News & Ratings for ConforMIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS and related companies with MarketBeat.com's FREE daily email newsletter.